Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
1/1/1999
1.
Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral TMX vs Weekly Intravenous 5-FU for Advanced Pancreatic Cancer (Summary Last Modified 01/99)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
21 and over
Pharmaceutical / Industry
ALFACELL-P30-300
NCI-V95-0752
Last Modified:
8/1/1998
2.
Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen vs Weekly Intravenous Gemcitabine for Advanced Pancreatic Cancer (Summary Last Modified 08/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
21 and over
Pharmaceutical / Industry
ALFACELL-P30-303
NCI-V96-0938
Last Modified:
10/29/2007
 
First Published:
12/1/1997
3.
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
21 and over
Pharmaceutical / Industry
ALFACELL-P30-302
NCI-V97-1273, NCT00003034
Last Modified:
3/1/1998
4.
Phase II Pilot Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen for Prostate Cancer Patients with an Elevated PSA After Failing Local Therapy (Summary Last Modified 03/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Pharmaceutical / Industry
ALFACELL-P30-400
NCI-V96-0937
Last Modified:
6/1/1997
5.
Phase II Study of P-30 Protein Administered as a Single Weekly Intravenous Bolus Dose in Advanced Malignant Mesothelioma (Summary Last Modified 06/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Other
TCSC-P-30-P/PHII
NCI-V92-0008
Last Modified:
2/1/1991
6.
Phase I Study of P-30 Protein Administered by Weekly Intravenous Bolus Injections in Patients with Cancer (Summary Last Modified 02/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
21 and over
TCSC-P-30-PROTEIN
NCI-V90-0188
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute